Education
About Us
Working with TipRanks
Follow Us
Sartorius AG (DE:SRT)
XETRA:SRT
Top Page
Sartorius
(XETRA:SRT)
Select Model
Select Model
Rating:65Neutral
Price Target:
€211.00
▲(7.22% Upside)
Sartorius's stock score is primarily driven by its strong operational efficiency and positive technical momentum. However, the high leverage and declining free cash flow present financial risks. The stock's high P/E ratio suggests potential overvaluation, which is a significant concern for valuation-focused investors.
Positive Factors
Revenue Growth
Consistent revenue growth, particularly in consumables, indicates strong market demand and effective sales strategies, supporting long-term business expansion.
Product Innovation
Continuous product innovation enhances competitive positioning and addresses evolving customer needs, fostering sustained growth and market leadership.
Profitability
Improved profitability through margin expansion reflects efficient operations and cost management, contributing to financial resilience and shareholder value.
Negative Factors
High Leverage
Significant leverage poses financial risks, potentially limiting strategic flexibility and increasing vulnerability to economic downturns.
Declining Free Cash Flow
Decreasing free cash flow may constrain the company's ability to invest in growth opportunities and manage debt, impacting long-term financial health.
Soft Equipment Business
Weak performance in the equipment segment suggests challenges in capital investment demand, potentially affecting overall revenue growth and market share.
Sartorius (SRT) vs. iShares MSCI Germany ETF (EWG)
Market Cap
€14.33B
Dividend Yield0.37%
Average Volume (3M)5.04K
Price to Earnings (P/E)94.6
Beta (1Y)1.47
Revenue Growth5.82%
EPS Growth59.90%
CountryDE
Employees13,573
SectorHealthcare
Sector Strength45
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)1.08
Shares Outstanding37,440,000
10 Day Avg. Volume4,524
30 Day Avg. Volume5,035
Financial Highlights & Ratios
PEG Ratio-2.98
Price to Book (P/B)5.37
Price to Sales (P/S)4.39
P/FCF Ratio26.21
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusModerate Buy
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Sartorius Business Overview & Revenue Model
Company DescriptionSartorius (SRT) is a global pharmaceutical and laboratory equipment supplier headquartered in Göttingen, Germany. The company operates primarily in the biopharmaceutical sector, providing a wide array of products and services, including laboratory instruments, bioprocess solutions, and consumables for the production of biopharmaceuticals. Sartorius is dedicated to advancing the health care and life science industries through innovative technologies and solutions that enhance the efficiency of research and production processes.
How the Company Makes MoneySartorius generates revenue through several key streams, primarily focused on the sale of laboratory and bioprocess equipment, consumables, and services. The company sells products such as balances, pipettes, filtration systems, and bioreactors, which are essential in laboratory and manufacturing settings. A significant portion of Sartorius's revenue comes from recurring sales of consumables, which are used in ongoing laboratory procedures and biopharmaceutical manufacturing. Additionally, Sartorius benefits from long-term partnerships with major pharmaceutical companies and research institutions, which often involve customized solutions and services, further enhancing their revenue. The company's focus on innovation and strategic acquisitions also plays a crucial role in expanding its product offerings and market reach, contributing to overall earnings growth.
Sartorius Earnings Call Summary
Earnings Call Date:Jul 22, 2025
(Q2-2025)
| % Change Since: |
Next Earnings Date:Jan 22, 2026
Earnings Call Sentiment Positive
The earnings call reflected a positive sentiment with strong growth in consumables and increased profitability. However, challenges in the equipment business and tariff impacts were noted, indicating a cautious outlook for the second half of the year.Q2-2025 Updates
Positive Updates
Strong Revenue Growth
Sartorius reported a revenue growth of 6% in constant currencies, driven by a strong increase in consumables sales. The Bioprocessing Solutions sales revenue grew by nearly 9% year-over-year on a constant currency basis.
Increased Profitability
The underlying EBITDA increased by 12% year-over-year, with the EBITDA margin approaching 30%. This margin expansion was driven by positive volume, product mix, and economies of scale.
Launch of New Products
Introduced new products in both bioprocessing and lab divisions, including a platform for incentivized bioprocesses and the new model of IncuCyte for real-time cell observation.
Confirmation of Full-Year Guidance
The company confirmed its full-year 2025 guidance, indicating confidence in meeting revenue and EBITDA margin targets.
Negative Updates
Soft Equipment Business
The equipment business remains soft, with continued hesitation around larger capital investments by customers, leading to a decline in sales revenue for the Lab Products & Services division by 4% in constant currency.
Tariff Challenges
Began facing tariff challenges starting April 2, with anticipated effects expected to increase over the second half of the year.
LPS Instrument Demand Lagging
Demand for Lab Products & Services instruments continues to lag expectations, contributing to the overall decline in the division's performance.
Company Guidance
During the H1 2025 conference call for Sartorius and Sartorius Stedim Biotech, the company provided several key financial metrics and guidance. Sartorius reported a 6% growth in revenue in constant currencies, with the underlying EBITDA increasing by 12% year-over-year, resulting in an EBITDA margin nearing 30%. Bioprocessing Solutions revenue grew by nearly 9% year-over-year, while Lab Products & Services saw a 4% decline in constant currency sales. The company confirmed its full-year 2025 guidance, projecting a 6% increase in constant currencies for the group, with EBITDA margins expected between 29% and 30%. Sartorius also highlighted its continued focus on innovation, mentioning new product launches and the completion of the MatTek acquisition, which will contribute to the financial results in the second half of the year. Despite uncertainties, Sartorius expressed confidence in meeting its full-year targets, supported by strong consumables demand and strategic investments in capacity and technology.Sartorius Financial Statement Overview
Summary
Sartorius demonstrates strong operational efficiency with solid gross and EBIT margins. However, challenges include high leverage and declining free cash flow, which could impact financial stability. Despite these challenges, the company maintains a strong market position.Income Statement
Sartorius shows a strong gross profit margin of 45.76% in TTM, indicating efficient production and pricing strategies. However, the net profit margin is relatively low at 3.86%, suggesting high operational costs or other expenses. Revenue growth has been inconsistent, with a notable decline in 2023 but a recovery in TTM. EBIT and EBITDA margins are healthy, reflecting good operational efficiency.72
Positive
Balance Sheet
The company has a high debt-to-equity ratio of 1.75 in TTM, indicating significant leverage, which could pose financial risks. Return on equity has decreased over the years, standing at 4.95% in TTM, reflecting lower profitability for shareholders. The equity ratio is moderate, suggesting a balanced asset financing approach.65
Positive
Cash Flow
Operating cash flow is robust, but free cash flow has declined by 16.30% in TTM, indicating potential challenges in cash generation. The operating cash flow to net income ratio is healthy, suggesting good cash conversion. However, the free cash flow to net income ratio indicates some pressure on cash flow relative to earnings.68
Positive
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.47B | 3.38B | 3.40B | 4.17B | 3.45B | 2.34B |
| Gross Profit | 1.59B | 1.52B | 1.57B | 2.20B | 1.84B | 1.21B |
| EBITDA | 860.00M | 786.80M | 873.10M | 1.50B | 945.12M | 662.13M |
| Net Income | 133.70M | 84.00M | 205.20M | 913.10M | 426.98M | 321.47M |
Balance Sheet | ||||||
| Total Assets | 10.03B | 10.10B | 9.76B | 6.98B | 5.70B | 4.70B |
| Cash, Cash Equivalents and Short-Term Investments | 871.80M | 828.70M | 394.20M | 196.80M | 360.99M | 217.65M |
| Total Debt | 4.66B | 4.56B | 5.31B | 2.54B | 2.08B | 2.09B |
| Total Liabilities | 6.23B | 6.21B | 7.00B | 4.32B | 3.98B | 3.30B |
| Stockholders Equity | 2.66B | 2.76B | 2.07B | 1.99B | 1.26B | 1.05B |
Cash Flow | ||||||
| Free Cash Flow | 575.30M | 566.30M | 293.90M | 211.60M | 458.65M | 271.27M |
| Operating Cash Flow | 918.80M | 976.20M | 853.60M | 734.20M | 865.81M | 511.52M |
| Investing Cash Flow | -354.40M | -425.80M | -2.82B | -1.13B | -569.61M | -1.27B |
| Financing Cash Flow | -344.00M | -128.30M | 2.17B | 209.90M | -165.18M | 907.47M |
Sartorius Technical Analysis
Positive
196.80
Price Trends
183.44
Positive
171.76
Positive
174.26
Positive
Market Momentum
4.64
Negative
62.93
Neutral
86.84
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:SRT, the sentiment is Positive. The current price of 196.8 is above the 20-day moving average (MA) of 185.77, above the 50-day MA of 183.44, and above the 200-day MA of 174.26, indicating a bullish trend. The MACD of 4.64 indicates Negative momentum. The RSI at 62.93 is Neutral, neither overbought nor oversold. The STOCH value of 86.84 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for DE:SRT.
Sartorius Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
69 Neutral | €26.51B | 23.43 | 7.50% | 2.10% | 0.63% | ― | |
67 Neutral | €48.55B | 22.73 | 11.45% | 2.18% | 4.53% | 10.12% | |
66 Neutral | €3.83B | 24.17 | 7.48% | 1.38% | 5.21% | -39.36% | |
66 Neutral | €49.00B | 17.11 | 10.32% | 1.82% | 1.47% | 9.64% | |
65 Neutral | €14.33B | 94.60 | 5.01% | 0.37% | 5.82% | 59.90% | |
60 Neutral | €11.96B | 18.40 | 5.41% | 3.60% | 2.10% | 9.19% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
DE:SRT
Sartorius
196.80
22.14
12.67%
DE:AFX
Carl Zeiss Meditec
43.44
-16.11
-27.05%
DE:FME
Fresenius Medical Care AG & Co. KGaA
40.04
-4.33
-9.75%
DE:FRE
Fresenius SE & Co. KGaA
47.55
14.59
44.27%
DE:MRK
Merck KGaA
120.65
-18.48
-13.28%
DE:SHL
Siemens Healthineers AG
43.51
-7.98
-15.50%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.